“An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s27. doi:10.25251/skin.4.supp.27.